Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C14H23NO |
Molecular Weight | 221.3385 |
Optical Activity | ( - ) |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC[C@H]([C@@H](C)CN(C)C)C1=CC=CC(O)=C1
InChI
InChIKey=KWTWDQCKEHXFFR-SMDDNHRTSA-N
InChI=1S/C14H23NO/c1-5-14(11(2)10-15(3)4)12-7-6-8-13(16)9-12/h6-9,11,14,16H,5,10H2,1-4H3/t11-,14+/m0/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/17656655Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/21476608 | https://www.nucynta.com/hcp/er/mechanism-of-action#isi-0
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17656655
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/21476608 | https://www.nucynta.com/hcp/er/mechanism-of-action#isi-0
Tapentadol is the first US FDA-approved centrally acting analgesic having both μ-opioid receptor agonist and noradrenaline (norepinephrine) reuptake inhibition activity with minimal serotonin reuptake inhibition. Tapentadol is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate, neuropathic pain associated with diabetic peripheral neuropathy (DPN) severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL233 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17656655 |
0.16 µM [Ki] | ||
Target ID: CHEMBL222 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17656655 |
8.8 µM [Ki] | ||
Target ID: CHEMBL228 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17656655 |
5.28 µM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | NUCYNTA Approved UseNUCYNTA ER (tapentadol) is indicated for the management of:
pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate
neuropathic pain associated with diabetic peripheral neuropathy (DPN) severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Launch Date2008 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
221.34 ng/mL |
86 mg single, oral dose: 86 mg route of administration: Oral experiment type: SINGLE co-administered: |
TAPENTADOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
221.34 ng × h/mL |
86 mg single, oral dose: 86 mg route of administration: Oral experiment type: SINGLE co-administered: |
TAPENTADOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.16 h |
86 mg single, oral dose: 86 mg route of administration: Oral experiment type: SINGLE co-administered: |
TAPENTADOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
4 h |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
TAPENTADOL plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
80% |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
TAPENTADOL plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes | ||||
yes | ||||
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/200533Orig1s000PharmR.pdf#page=22 Page: 22.0 |
PubMed
Title | Date | PubMed |
---|---|---|
Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes. | 2008 Jan |
|
Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study. | 2009 Feb |
|
A randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain. | 2009 Mar |
|
[Tapentadol. Opioid analgesic and norepinephrine reuptake inhibitors]. | 2010 Dec |
|
Stereochemical basis for a unified structure activity theory of aromatic and heterocyclic rings in selected opioids and opioid peptides. | 2010 Feb 18 |
|
Tapentadol immediate release: a new treatment option for acute pain management. | 2010 Feb 8 |
|
In vitro and in vivo characterization of tapentadol metabolites. | 2010 Jan-Feb |
|
Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain: tapentadol, a step toward a solution? | 2010 Jul |
|
Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain. | 2010 Jun |
|
Tapentadol immediate-release for acute pain. | 2010 Jun |
|
Recent advances in postoperative pain management. | 2010 Mar |
|
Determination of tapentadol and its metabolite N-desmethyltapentadol in urine and oral fluid using liquid chromatography with tandem mass spectral detection. | 2010 Oct |
|
Determination of tapentadol (Nucynta®) and N-desmethyltapentadol in authentic urine specimens by ultra-performance liquid chromatography-tandem mass spectrometry. | 2010 Oct |
|
Cost-effectiveness analysis of tapentadol immediate release for the treatment of acute pain. | 2010 Sep |
|
Comparative pharmacokinetics and bioavailability of tapentadol following oral administration of immediate- and prolonged-release formulations. | 2013 Apr |
|
Tapentadol hydrochloride: A novel analgesic. | 2013 Jul |
Sample Use Guides
As with many centrally-acting analgesic medications, the dosing regimen of NUCYNTA® should be individualized according to the severity of pain being treated, the previous experience with similar drugs and the ability to monitor the patient.
Initiate NUCYNTA® with or without food at a dose of 50 mg, 75 mg, or 100 mg every 4 to 6 hours depending upon pain intensity. On the first day of dosing, the second dose may be administered as soon as one hour after the first dose, if adequate pain relief is not attained with the first dose. Subsequent dosing is 50 mg, 75 mg, or 100 mg every 4 to 6 hours and should be adjusted to maintain adequate analgesia with acceptable tolerability. Daily doses greater than 700 mg on the first day of therapy and 600 mg on subsequent days have not been studied and are, therefore, not recommended.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27317026
Upon exposure to tramadol and tapentadol concentrations up to 600μM, cell toxicity was assessed through evaluation of oxidative stress, mitochondrial and metabolic alterations, as well as cell viability and death mechanisms through necrosis or apoptosis, and related signalling. Tapentadol was observed to trigger much more prominent toxic effects than tramadol, ultimately leading to energy deficit and cell death.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175690
Created by
admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
|
||
|
NCI_THESAURUS |
C241
Created by
admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
|
||
|
WHO-VATC |
QN02AX06
Created by
admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
|
||
|
WHO-ATC |
N02AX06
Created by
admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
|
||
|
LIVERTOX |
923
Created by
admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
|
||
|
DEA NO. |
9780
Created by
admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
|
||
|
NDF-RT |
N0000000174
Created by
admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
7477
Created by
admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
|
PRIMARY | |||
|
8309
Created by
admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
|
PRIMARY | |||
|
C72139
Created by
admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
|
PRIMARY | |||
|
DTXSID30170003
Created by
admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
|
PRIMARY | |||
|
759619
Created by
admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
|
PRIMARY | |||
|
DB06204
Created by
admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
|
PRIMARY | |||
|
m10459
Created by
admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
|
PRIMARY | Merck Index | ||
|
9838022
Created by
admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
|
PRIMARY | |||
|
4283
Created by
admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
|
PRIMARY | |||
|
175591-23-8
Created by
admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
|
PRIMARY | |||
|
Tapentadol
Created by
admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
|
PRIMARY | |||
|
H8A007M585
Created by
admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
|
PRIMARY | |||
|
TAPENTADOL
Created by
admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
|
PRIMARY | |||
|
H8A007M585
Created by
admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
|
PRIMARY | |||
|
QQ-108
Created by
admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
|
PRIMARY | |||
|
SUB31821
Created by
admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
|
PRIMARY | |||
|
C523979
Created by
admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
|
PRIMARY | |||
|
8216
Created by
admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
|
PRIMARY | |||
|
100000124502
Created by
admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
|
PRIMARY | |||
|
CHEMBL1201776
Created by
admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
|
PRIMARY | |||
|
787390
Created by
admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
|
PRIMARY | RxNorm |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE INACTIVE (PARENT)
METABOLITE INACTIVE (PARENT)
METABOLITE INACTIVE (PARENT)
METABOLITE INACTIVE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)